BRIEF published on 12/05/2024 at 13:05, 1 year 3 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 3 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 3 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 3 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 4 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 4 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 4 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 4 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 5 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 5 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 03/25/2026 at 19:15, 4 hours 22 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 10 hours 7 minutes ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 10 hours 7 minutes ago Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/25/2026 at 13:25, 10 hours 12 minutes ago Predictiv AI Expands Active Deployment of CloudRep.ai Across Healthcare, Retail, Real Estate, Travel and Global Markets
Published on 03/25/2026 at 20:00, 3 hours 36 minutes ago Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 3 hours 55 minutes ago EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 4 hours 6 minutes ago AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 4 hours 10 minutes ago EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 18:40, 4 hours 56 minutes ago TULKUBASH AND KYZYLTASH MINING ASSETS: DECLARATION FROM A GROUP OF INVESTORS
Published on 03/25/2026 at 18:31, 5 hours 5 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 5 hours 52 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
